Clinical Trials
247 trialsNCT03595124 2026-05-27
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04126070 2026-05-27
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03646461 2026-05-22
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
University of California, San Diego
Phase 2 Terminated
NCT03367741 2026-05-19
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04019964 2026-05-15
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05846659 2026-05-15
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
NCT01703949 2026-05-12
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
University of Washington
Phase 2 Active not recruiting
NCT02314169 2026-05-12
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03038672 2026-05-12
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04205409 2026-05-12
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
Phase 2 Completed
NCT03637543 2026-05-08
Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT03927105 2026-05-07
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03355560 2026-05-06
Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy
University of Cincinnati
Phase 2 Completed
NCT05144529 2026-05-05
TOP2101
Duke University
Phase 2 Terminated
NCT03057795 2026-05-01
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03799445 2026-04-30
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02257528 2026-04-29
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03789110 2026-04-28
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03981146 2026-04-22
ANICCA
University of Birmingham
Phase 2 Completed
NCT02275533 2026-04-13
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02656706 2026-04-13
Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma
Brown University
Phase 2 Active not recruiting
NCT03914300 2026-04-13
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04079712 2026-04-13
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06101134 2026-04-09
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT03158129 2026-04-06
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02873962 2026-04-01
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03620019 2026-03-27
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT04785820 2026-03-27
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Hoffmann-La Roche
Phase 2 Completed
NCT02829918 2026-03-11
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03071406 2026-03-11
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04166383 2026-03-10
VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03999749 2026-03-09
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 2 Active not recruiting
NCT04091750 2026-03-03
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
Georgetown University
Phase 2 Active not recruiting
NCT03785210 2026-02-23
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03366766 2026-02-20
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT04526730 2026-02-20
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT04552223 2026-02-11
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
University of Miami
Phase 2 Completed
NCT03203473 2026-02-06
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04938232 2026-02-05
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02919683 2026-01-28
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
NCT02648997 2026-01-26
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03829722 2026-01-22
Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03285321 2026-01-20
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT03267498 2026-01-12
Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)
University of California, San Francisco
Phase 2 Completed
NCT03425331 2026-01-08
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT04326257 2026-01-08
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
Phase 2 Completed
NCT04567615 2026-01-08
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
Bristol-Myers Squibb
Phase 2 Completed
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed